title: Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders.
abstract: OBJECTIVE
  To estimate the value of estrogen receptor (ER) in benign breast diseases and to find out if the response of benign breast diseases to danazol depends on the ER status of the tissue.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  University hospital, India.
  
  
  METHODS
  Samples of tissue from benign breast lesions, 40 fibrocystic disease and 10 fibroadenomas.
  
  
  METHODS
  Enzyme immunoassay for the presence of cytosolic ER.
  
  
  METHODS
  ER concentrations, and correlation with effect of treatment with danazol.
  
  
  RESULTS
  Fibrocystic disease and fibroadenomas showed 30% and 40% ER positivity, respectively. The mean (SD) ER concentration was significantly higher in premenopausal than postmenopausal patients 14.75 (3.79) fmol/mgm compared with 6.2 (1.59) fmol/mg (p < 0.05). All ten patients with mastalgia who had ER-positive lesions (n = 26) responded to danazol, compared with 6 of 16 patients who had ER-negative lesions (p < 0.05). Lesions with diffuse fibrosis (n = 14) and five with lymphocytic infiltration on histology were all ER-negative.
  
  
  CONCLUSIONS
  The patients with ER positive breast disease responded better to danazol than patients with ER negative breast disease.
authors.affiliation: Department of Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. akk_dr@satyam.net.in
authors.forename: A K
authors.initials: AK
authors.lastname: Khanna
authors.forename: J K
authors.initials: JK
authors.lastname: Tapodar
authors.forename: H D
authors.initials: HD
authors.lastname: Khanna
authors.forename: S
authors.initials: S
authors.lastname: Khanna
authors.forename: Anuradha
authors.initials: A
authors.lastname: Khanna
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D003613:Danazol / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D018226:Fibroadenoma / Q000188:drug therapy* / Q000378:metabolism*; D005348:Fibrocystic Breast Disease / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D003613:Danazol